Remebot

Remebot holds the leading position in China’s neurosurgical robot market, commanding 52.6% market share according to Frost & Sullivan’s 2023 report. Founded in 2010 by Da Liu, a graduate of Professor Tianmiao Wang’s robotics lab at Beihang University, the company has pioneered surgical navigation and positioning technology across neurosurgery and dental implantology.

Company Overview

Beijing Baihui Weikang Technology Co., Ltd. emerged from over two decades of surgical robotics research at Beihang University. The founding team’s work on frameless stereotactic neurosurgery began in 1999, leading to breakthroughs in robotic navigation that eliminated the need for traditional head-frame fixation. This technology foundation enabled Remebot to develop China’s first NMPA-approved neurosurgical robot in 2018.

The company operates as a National-level Specialized and Innovative “Little Giant” enterprise, recognized for its contributions to high-end medical device manufacturing. The research team has received the National Science and Technology Progress Award (Second Class) and the Beijing Science and Technology Progress Award (First Class). Their work has been published in Nature and other SCI-indexed journals.

Remebot maintains two core product brands: the Remebot neurosurgical robot series (睿米®) and the Remebot Dental robot (瑞医博®). A wholly-owned subsidiary, Beijing Ruiyibo Technology Co., Ltd., operates the dental product line independently.

Core Products

Remebot Neurosurgical Robot Series

The Remebot neurosurgical platform integrates multi-modal image fusion (CT, MRI, PET, DTI), automatic positioning, and real-time navigation. Eight product variants have received NMPA Class III medical device registration certificates, ranging from the flagship RM-200 for comprehensive tertiary hospitals to the RM-50 series designed for hemorrhagic stroke treatment in primary care settings.

The system achieves positioning accuracy within 0.5mm and completes patient registration in under 2 minutes. It supports nearly 100 surgical procedures across 12 categories, including hematoma aspiration, percutaneous puncture, craniotomy navigation, and endoscopic neurosurgery. The platform was China’s first domestically developed robot to perform deep brain stimulation (DBS) surgery.

Remebot Dental Robot

The dental implant robot received NMPA approval in 2021 as China’s first oral surgery robot. It employs optical tracking at 1,000 Hz frequency to monitor patient movement with 0.1mm sensitivity, enabling real-time trajectory correction during procedures. Clinical studies report mean deviations of 0.74mm coronally, 0.73mm apically, and 1.11° angularly.

Technology & Innovation

Remebot has achieved full domestic localization of core components, including proprietary optical tracking systems and surgical-grade robotic arms. This breakthrough addresses previous dependence on imported components and enables cost-effective deployment to primary healthcare facilities.

The company holds over 140 intellectual property rights, including 54 invention patents. Key technologies include:

• Multi-spectral optical tracking and positioning
• Real-time patient motion compensation
• Force-sensing control for safe tissue interaction
• AI-powered image segmentation and surgical planning

Market Presence

As of 2024, Remebot neurosurgical robots operate in over 400 hospitals across all 31 provincial-level administrative regions in China. The platform has supported more than 40,000 clinical procedures, with 8,000+ surgeries completed in 2023 alone. In 2023, Remebot achieved 40 unit orders, representing 52.6% of China’s neurosurgical robot market.

International expansion began in March 2024 with the first overseas installation in Kazakhstan, marking the debut of Chinese neurosurgical robots abroad. The company has since expanded into Central Asia, Southeast Asia, and South America.

Key Milestones

• 2010: Company founded in Beijing
• 2018: First neurosurgical robot (RM-100) receives NMPA approval, becoming China’s first approved neurosurgical robot
• 2019: Selected for Ministry of Industry and Information Technology neurosurgical robot demonstration project with 9 leading hospitals
• 2020: Completed Series D funding of ¥430 million; accumulated funding exceeds ¥600 million
• 2020: Second-generation RM-200 receives NMPA approval
• 2021: First dental implant robot receives NMPA approval as China’s first oral surgery robot; designated Beijing Engineering Research Center
• 2021: First 5G remote DBS surgery completed at Beijing Tiantan Hospital
• 2022: RM-50 receives approval as first neurosurgical robot with fully localized core components
• 2024: Multiple new models (RM-260, RM-150, RM-50B/T/TF) receive NMPA approval; international market entry with Kazakhstan installation
• 2025: New dental navigation device receives NMPA approval

Frequently Asked Questions

What is Remebot’s market position in China?

Remebot leads China’s neurosurgical robot market with 52.6% share as of 2023, according to Frost & Sullivan. Combined with Huake Precision, domestic manufacturers hold over 80% of the Chinese neurosurgical robot market.

Is Remebot publicly traded?

No, Remebot remains privately held. The company completed Series D funding of ¥430 million in December 2020, with total accumulated funding exceeding ¥600 million.

What distinguishes Remebot from imported neurosurgical robots?

Remebot has achieved full localization of core components including optical tracking systems and robotic arms. This reduces costs significantly compared to imported alternatives, enabling deployment to county-level hospitals in remote regions. The visible-light tracking technology (versus laser-based systems used by some competitors) enables faster registration and multi-dimensional real-time tracking.

Does Remebot have international regulatory approvals?

While Remebot products have NMPA approval in China, CE Mark and FDA clearance status has not been publicly confirmed. The company began international commercial deployment in 2024 with installations in Kazakhstan.